A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D 3 , and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands. In a mammalian twohybrid assay, we have found that recruitment of a VP16-RXR chimera by a Gal4-TR␤ ligand-binding domain fusion is enhanced up to 50-fold by thyroid hormone (T 3 ). This was also observed with a mutant fusion, Gal4-TR(L454A), lacking ligand-inducible activation function (AF-2) and unable to interact with putative coactivators, suggesting that the AF-2 activity of TR or intermediary cofactors is not involved in this effect. The wild-type and mutant Gal4-TR fusions also exhibited hormonedependent recruitment of RXR in yeast. Hormone-dependent recruitment of RXR was also evident with another Gal4-TR mutant, AHTm, which does not interact with the nuclear receptor corepressor N-CoR, suggesting that ligand-enhanced dimerization is not a result of T 3 -induced corepressor release. Finally, we have shown that the interaction between RXR and TR is augmented by T 3 in vitro, arguing against altered expression of either partner in vivo mediating this effect. We propose that ligand-dependent heterodimerization of TR and RXR in solution may provide a further level of control in nuclear receptor signaling.
The thyroid hormone receptor (TR) 1 is a member of the nuclear receptor superfamily of ligand-inducible transcription factors. A subset of receptors, including those for estrogen and glucocorticoid, bind to regulatory sequences in target gene promoters as homodimers, with cooperative DNA binding and dimerization mediated by regions within their DNA-and ligand-binding domains (1) (2) (3) (4) (5) (6) (7) . The thyroid hormone receptor is also capable of binding to thyroid hormone response elements (TREs) as a monomer or homodimer, but the latter complex is known to dissociate in the presence of thyroid hormone (T 3 ) (8 -11) . More recently, it has been shown that TR as well as receptors for vitamin D 3 , retinoic acid (RAR), and eicosanoids form heterodimeric complexes with an auxiliary factor, the retinoid X receptor (RXR) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The TR⅐RXR heterodimer binds TREs with higher affinity than TR alone and remains stable in the presence of T 3 (8 -11) , suggesting that this complex mediates ligand-dependent transcriptional activation.
The isolated DNA-binding domains (DBDs) of TR and RXR are capable of both cooperative binding to and discrimination of direct repeat TREs (23) . The dimerization interface between DBDs was mapped initially by mutational analyses (24) and then elucidated from the crystal structure of TR⅐RXR DBDs bound to a DR4 TRE (25) . A separate dimerization interface in the carboxyl-terminal domains of nuclear receptors was first delineated as a series of nine conserved hydrophobic heptad repeats (26) predicted to form ␣-helices with the potential to mediate a coiled-coil protein interaction. A 40-amino acid region encompassing the ninth heptad has been shown to be critical for heterodimerization (27) . This region is almost coincident with helical segments (helices 9 and 10) that constitute the dimer interface in the crystal structure of the ligand-binding domain (LBD) of hRXR␣ (28) . In addition, mutation of hydrophobic residues at either end of this heptad in TR or RAR abolishes the interaction with RXR (10, 29, 30) .
Several studies have shown a solution interaction between RXR and other nuclear receptors in the absence of DNA or ligand. Thus, RAR⅐RXR or TR⅐RXR complexes can be coimmunoprecipitated in the absence of ligand (18 -20) , and a constitutive interaction between the LBDs of RXR and RAR (31) or TR (10, 32) has been demonstrated in mammalian cells and yeast (33) . However, the influence of ligand on dimerization between RXR and TR is unclear. In this study, we have investigated the role of T 3 in modulating the interaction between the LBDs of TR␤ and RXR␣.
MATERIALS AND METHODS
Expression Vectors and Reporter Constructs-The wild-type pSG-TR and pSG-RXR mammalian expression vectors, respectively, contain the LBDs of human TR␤ (amino acids 174 -461) and RXR␣ (amino acids 198 -462) coupled to the Gal4 DBD (amino acids 1-147) in pSG424. Mutant expression vectors include pSG-TR(L454A), containing a L454A substitution (32) , and pSG-TR(AHTm), with the triple substitution A223G/H224G/T227A in pSG-TR. pVP-RXR-(1-462) and pVP-RXR(DE) consist of either full-length or the LBD (amino acids 198 -462) of hRXR␣, respectively, coupled to the activation domain of VP16 in the expression vector pAASV. The reporter plasmid UAStkLUC contains Gal4 recognition sequences and the thymidine kinase promoter in * This work was supported by the Wellcome Trust, the Medical Research Council (United Kingdom), and the Imperial Cancer Research Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Equal first authors. 1 The abbreviations used are: TR, thyroid hormone receptor; TRE, thyroid hormone response element; T 3 , thyroid hormone; RAR, retinoic acid receptor; RXR, retinoid X receptor; hRXR␣, human retinoid X receptor ␣; DBD, DNA-binding domain; LBD, ligand-binding domain;pA 3 LUC. The internal control plasmid Bos-␤gal contains the promoter of human elongation factor 1␣ linked to ␤-galactosidase (32) . The yeast expression vectors pMA-TR(wt) and pMA-TR(L454A) contain the LBDs of either wild-type human TR␤ or the L454A mutant described above coupled to the Gal4 DBD in pMA424, respectively, and pMA210 contains full-length Gal4 cDNA. pGAD-RXR consists of residues 198 -462 of hRXR␣ coupled to the activation domain of Gal4 in pGAD10. The bacterial expression vector pGEX-RXR contains full-length hRXR␣ linked to glutathione S-transferase (GST) in pGEX2T.
Mammalian Cell Culture and Transfections-JEG-3 human choriocarcinoma cells were cultured in Opti-MEM supplemented with 2% (v/v) fetal bovine serum and 1% penicillin/streptomycin/Fungizone and transferred to Opti-MEM with 1% penicillin/streptomycin/Fungizone prior to transfection by a 4-h exposure to calcium phosphate as described previously (10) . Following a 36-h incubation, cells were lysed, and luciferase activity was measured and normalized using ␤-galactosidase activity.
Yeast ␤-Galactosidase Assays-SFY526 yeast cells were cultured and cotransformed with the appropriate expression vectors and assayed following the protocol detailed by the manufacturer (CLONTECH). ␤-Galactosidase activity in liquid culture assays was corrected for cell density. Cells were grown in the absence or presence of 1 M triiodothyroacetic acid (TRIAC).
Protein-Protein Interaction Assays-GST-RXR fusion protein was expressed in Escherichia coli and purified as described previously (32) . [ 35 S]Methionine-labeled Gal4-TR␤ was synthesized by coupled in vitro transcription and translation. Aliquots of GST-RXR immobilized on glutathione-Sepharose were preincubated with 4 mg ml Ϫ1 bovine serum albumin in P buffer (50 mM Tris-HCl, 0.1 M KCl, 0.14 M NaCl, 0.5% Nonidet P-40, 10% glycerol, and 2 mM dithiothreitol, pH 8.0) at room temperature prior to 10-fold dilution in P buffer and equilibration at 37°C. Aliquots of in vitro translated Gal4-TR were diluted in P buffer in the absence or presence of 5 M T 3 and equilibrated at 30°C for 1 h to allow saturation with ligand. Equal volumes of the GST-RXR and Gal4-TR solutions were then mixed and incubated at 37°C for the specified duration, followed by washing four times with 20 mM TrisHCl, 0.1 M NaCl, 1 mM EDTA, and 0.5% Nonidet P-40, pH 8.0, and analysis by SDS-polyacrylamide gel electrophoresis. Gels were stained with Coomassie Blue to check for equal loading of fusion protein and then exposed to autoradiography.
RESULTS

Gal4-TR and VP16-RXR Chimeras Interact in Vivo-
To examine the interaction between the ligand-binding domains of TR and RXR, we used a mammalian two-hybrid assay in which chimeric proteins containing the LBDs of human TR␤ or hRXR␣ or full-length hRXR␣ were fused to either the Gal4 DBD or the VP16 activation domain and coexpressed in JEG-3 cells (Fig. 1) . Transfection of either receptor fusion with the Gal4 DBD or VP16 alone resulted in negligible transcriptional activity. Similarly, coexpression of Gal4-TR and VP16-TR or Gal4-RXR and VP16-RXR did not enhance promoter activity. However, cotransfection of TR and RXR chimeras resulted in a significant increase in reporter gene activity, suggesting that a constitutive interaction between the LBDs of these receptors does occur in vivo.
T 3 Enhances the Interaction of Gal4-TR with VP16-RXRSince transcriptional activation by nuclear receptors is generally dependent on cognate ligand, we next examined the influence of T 3 in the above paradigm. As noted previously, there was a significant constitutive interaction between Gal4-TR(wt) and VP16-tagged full-length RXR or the RXR LBD (Fig. 2 , bars 2 and 3). The addition of thyroid hormone enhanced reporter gene activity by 25-50-fold. One interpretation of this finding was that the additional activation represented increased recruitment of VP16-RXR to the promoter via its interaction with Gal4-TR. However, T 3 also significantly augmented the activity of Gal4-TR alone (Fig. 2, bar 1 ), presumably by stimulating the known ligand-dependent transcriptional activation function (AF-2) contained within the TR LBD. This raised the possibility that the ligand-dependent increase in reporter activation was due to the AF-2 activity of TR superimposed on activation associated with the VP16 moiety.
T 3 -mediated Enhancement Is Not Due to AF-2 Activity of Gal4-TR-To differentiate between these possibilities, we used a mutant Gal4-TR fusion containing a single amino acid substitution (L454A) in the carboxyl-terminal amphipathic ␣-helix that abolishes the AF-2 activity of TR without altering its ligand binding function (32) . The mutant Gal4-TR(L454A) chimera also exhibited constitutive interaction with VP16-RXR (Fig. 2, bars 5 and 6) , and again, reporter activity was markedly enhanced with the addition of T 3 . However, the mutant Gal4-TR(L454A) fusion exhibited no ligand-dependent transcriptional activation when tested alone (Fig. 2, bar 4) , suggesting that the T 3 -dependent increase in reporter activity was not due to AF-2 activity, but rather to an increased recruitment of VP16-RXR.
T 3 Enhances Gal4-TR and VP16-RXR Interaction in Yeast-
Although full-length TR␤ has been shown to exhibit both constitutive and ligand-dependent activation functions with TREcontaining reporter genes in yeast (34) , a chimera consisting of the TR␤ LBD coupled to the DBD of LexA was transcriptionally inactive in Saccharomyces cerevisiae (33) . This lack of AF-2 activity in yeast prompted us to examine the influence of ligand on the interaction of TR and RXR LBDs to substantiate our findings in mammalian cells. Wild-type or mutant (L454A) Gal4-TR fusions were cotransformed into yeast with either the activation domain (AD) of Gal4 alone or a chimera containing the LBD of RXR fused to the activation domain (AD-RXR). Recombinant yeast cells were grown either in the absence or presence of TRIAC prior to detection of ␤-galactosidase expression (Fig. 3A) . Treatment with TRIAC did not induce ␤-galactosidase activity with coexpressed Gal4-TR(wt) and AD, but ligand markedly enhanced ␤-galactosidase expression with a Gal4-TR(wt) and AD-RXR combination. To exclude the possibility that the coexpressed RXR was simply facilitating the inherent AF-2 activity of Gal4-TR, we tested the Gal4-TR(L454A) mutant and found a comparable TRIAC-dependent enhancement of ␤-galactosidase activity with AD-RXR. To quantify the magnitude of the ligand-dependent enhancement, yeast cells containing either wild-type or mutant (L454A) Gal4-TR fusions, together with either AD or AD-RXR, were grown in the absence or presence of TRIAC, and cell extracts were assayed for ␤-galactosidase activity (Fig. 3B) . The results confirmed that neither the wild-type nor the mutant (L454A) Gal4-TR fusions exhibit AF-2 activity following TRIAC treatment. Both fusions showed a comparable constitutive association with coexpressed AD-RXR that was enhanced 20 -25-fold by the addition of TRIAC.
T 3 Enhancement Is Not Due to Corepressor Release-Unliganded TR is known to mediate repression of basal gene transcription, and this silencing function has been localized to its LBD (35, 36) . Recently, two putative corepressor proteins (NCoR and SMRT) have been identified that bind TR⅐RXR heterodimers in the absence of ligand, but that dissociate following ligand binding (37, 38) . This raised the possibility that ligandinduced release of corepressor(s) by promoter-bound Gal4-TR⅐VP16-RXR complexes could account for the T 3 -dependent increased reporter activity observed in two-hybrid assays. To discount this possibility, we studied another mutant Gal4-TR fusion, AHTm, which contains a triple substitution (A223G/ H224G/T227A) 2 that has been shown to abolish the interaction of the TR⅐RXR heterodimer with N-CoR (38) . When tested independently (Fig. 4, bar 2) , hormone-dependent reporter gene activation by Gal4-TR(AHTm) was preserved, but signif- 2 The original codon nomenclature has been altered to correspond to the sequence containing 461 residues (39). icantly reduced (15%) compared with Gal4-TR(wt) (bar 1), indicating that this mutant receptor retains ligand binding and activation functions. The Gal4-TR(AHTm) mutant unexpectedly showed negligible constitutive interaction with coexpressed VP16-RXR compared with the wild-type receptor fusion (Fig. 4, bars 3 and 4) . Following T 3 treatment, there was a significant enhancement of reporter activity with Gal4-TR(wt), as seen previously, but in addition, Gal4-TR(AHTm) mediated a similar response, suggesting that corepressor release did not account for this effect.
T 3 Enhances TR⅐RXR Heterodimer Formation in Vitro-To determine whether T 3 could enhance dimerization between the TR and RXR LBDs, we utilized an in vitro protein-protein interaction assay in which GST-RXR␣ was incubated with the [ 35 S]methionine-labeled Gal4-TR(wt) chimera in the absence or presence of T 3 . The results indicated a weak constitutive association between these two proteins in the absence of hormone, which did not change upon extended coincubation (Fig. 5, A and  B) . However, in the presence of 1 M T 3 , the TR-RXR interaction was enhanced by up to 10-fold, reaching a maximum after ϳ40 min of coincubation (Fig. 5 (A and B) and data not shown).
9-cis-RA Attenuates the Recruitment of VP16-RXR by Gal4
-TR-Finally, we examined the influence of 9-cis-RA, the ligand for RXR, on the interaction of Gal4-TR and VP16-RXR in the mammalian cell two-hybrid system. Either the Gal4 DBD or Gal4-TR(L454A) was coexpressed with VP16-tagged full-length RXR or the RXR LBD. The presence of 1 M 9-cis-RA, in the absence of T 3 , attenuated the constitutive interaction of Gal4-TR(L454A) with VP16-RXR, particularly with the full-length VP16-RXR fusion (Fig. 6, bar 9 versus bar 11) . The enhanced interaction of Gal4-TR(L454A) with VP16-RXR following T 3 was also attenuated by 9-cis-RA (Fig. 6, bar 6 
versus bars 8 and 10 versus bar 12).
DISCUSSION
Heterodimerization between TR and RXR is a central mechanism for T 3 -induced regulation of many target gene promoters. While a number of studies in vitro have suggested that the formation of TR⅐RXR complexes on DNA is not significantly influenced by ligand, the role of hormone in mediating solution interactions between these receptors has not been elucidated. Here we have shown a constitutive heterodimeric interaction between the LBDs of TR and RXR in the absence of ligand, confirming earlier observations (20, 32, 40) , while in addition demonstrating a lack of homodimeric interaction for either LBD. This latter finding suggests that the two receptor LBDs possess complementary dimerization interfaces and, furthermore, that their DBDs and the response element to which they bind also play a major role in determining the nature of the dimeric complex since TR⅐TR and RXR⅐RXR homodimers do form readily on DNA (24, 41, 42) . We have made the additional observation that the addition of T 3 markedly increased reporter gene activity up to 50-fold in cells containing coexpressed Gal4-TR and VP16-RXR fusion proteins, suggesting that T 3 enhances the recruitment of VP16-RXR to promoter-associated Gal4-TR. However, alternative explanations were also examined.
The possibility that the enhanced activity represented T 3 -mediated induction of the ligand-dependent transactivation function (AF-2) present in the TR LBD was discounted since this effect was also observed with the mutant thyroid hormone receptor fusion protein Gal4-TR(L454A), which lacks AF-2 activity, as well as in yeast, where the AF-2 function of the TR LBD is not manifest. The suggestion that the apparent enhanced recruitment of VP16-RXR was due to T 3 -mediated release of corepressor(s) was eliminated since Gal4-TR(AHTm), which contains mutations shown to abrogate the interaction with the putative transcriptional corepressor N-CoR (38) , also showed T 3 -dependent recruitment of VP16-RXR. Furthermore, while previously reported T 3 -induced dissociation of TR homodimers may facilitate interaction of the Gal4-TR monomer with RXR (9, 11), the data in Fig. 1 show no evidence of TR LBD homodimer formation. We considered the possibility that the apparent enhanced recruitment of VP16-RXR was not due to augmentation of a direct interaction between TR and RXR LBDs, but the result of ligand-dependent recruitment of additional cofactors, capable of binding to either receptor partner and promoting their interaction (43) . Using a two-hybrid assay system in mammalian cells, Kraus et al. (44) have shown a ligand-dependent interaction between the amino-and carboxyl-terminal regions of the estrogen receptor that is markedly attenuated by a mutation in the AF-2 region of the carboxylterminal domain. One mechanism proposed by the authors involved ligand-dependent recruitment of an accessory factor to the AF-2 region, thereby facilitating the interaction between the two receptor regions. However, our data do not favor such a mechanism for two reasons. First, we have recently shown that the L454A mutation in the AF-2 region of TR abrogates its ligand-dependent interaction with at least two putative intermediary proteins (SRC-1 and RIP140) (45) , yet Gal4-TR(L454A) retained the ability to recruit VP16-RXR in response to ligand; second, we have also shown that T 3 can enhance the association of Gal4-TR and GST-RXR by up to 10-fold (Fig. 5, A and B) in vitro, a context in which facilitation by auxiliary factors is unlikely. Furthermore, the in vitro data also rule out the possibility that the augmented reporter gene activity in vivo was mediated by a ligand-dependent alteration in Gal4-TR expression or stability leading to increased VP16-RXR recruitment.
There is precedent for our observations from previous studies with other members of the nuclear receptor family. Ligand-dependent homodimerization between fusion proteins containing the activation or DNA-binding domains of Gal4 linked to the full-length estrogen receptor has been demonstrated using a two-hybrid assay system in yeast (46) . The solution interaction of the vitamin D 3 receptor with GST-RXR, in the absence of DNA, has been examined using surface plasmon resonance (47) . The addition of the ligand 1,25-dihydroxyvitamin D 3 enhanced the affinity of the vitamin D 3 receptor for RXR by 7-fold as a result of an increase in the association rate constant, and we hypothesize that the T 3 -mediated enhancement of the TR-RXR interaction might involve a similar mechanism. Another example in which ligand promotes dimerization is provided by the ecdysone receptor-ultraspiracle interaction, where muristerone has been shown to promote formation of ecdysone receptor-ultraspiracle complexes as well as formation of ecdysone receptor-ultraspiracle or ecdysone receptor-RXR heterodimers on DNA (48) . Last, a genomic footprinting study has shown that occupancy of the retinoid response element in the RAR␤2 gene occurs only after treatment of cells with retinoic acid (49) . Although it was suggested that this might represent an enhanced affinity of the liganded RAR⅐RXR heterodimer for DNA, the effect may also be due to a ligand-dependent increase in solution heterodimer formation.
Studies using circular dichroism spectroscopic analysis have provided evidence for a ligand-induced conformational change in TR, while gel shift experiments have shown that the mobility of DNA-bound complexes is increased with T 3 (9, 11, 50) . Crystallographic studies of the LBD of the ␣ isoform of TR, which is highly homologous to TR␤ (51), also suggest an influence of ligand binding on dimerization. The ninth heptad repeat of TR is at the amino-terminal end of helix 11, on the surface of which are many residues implicated in dimerization. However, residues at the carboxyl-terminal end of helix 11 border the hormone-binding cavity and form critical contacts with ligand. This involvement of helix 11 in both functions is in keeping with the colocalization of ligand binding and dimerization to a similar region in the estrogen receptor (3). Evidence in favor of this relationship is provided by the observation that the effect of a ninth heptad mutation (L421R in human TR␤, L365R in chick TR␣, and M377R in human RAR␣), which abolishes the interaction of a number of receptors with RXR can be reversed by the addition of cognate ligand, suggesting a role for hormone in stabilizing dimerization (10, 30) . The Gal4-TR(AHTm) triple mutant used in this study also failed to interact with RXR in the absence of ligand, suggesting that these residues, which lie within helix 1, either constitute part of the dimerization interface or allosterically influence the integrity of dimerization regions. However, with T 3 , the interaction of Gal4-TR(AHTm) with VP16-RXR was fully restored, emphasizing the central role of ligand binding in stabilizing the integrity of the LBD and thereby promoting the formation of a dimerization interface.
Although RXR enhances DNA binding by TR and subsequent T 3 -induced receptor signaling, the role of 9-cis-RA in TR⅐RXR dimerization is unclear. The RXR moiety of DNA-bound receptor heterodimers typically binds to the 5Ј-half site of a TRE (23, 52, 53) , but is unable to bind 9-cis-RA due to the negative allosteric influence of its dimer partner (54, 55) . We found that 9-cis-RA inhibited both the constitutive and T 3 -induced interaction of Gal4-TR with VP16-RXR in the two-hybrid assay. 9-cis-RA-mediated inhibition of the constitutive TR-RXR interaction suggests that this effect is not due to disruption of T 3 occupancy of TR by an inhibitory allosteric influence of liganded RXR. An alternative possibility is that 9-cis-RA induces dimerization of the VP16-RXR fusion to itself or endogenous RXR or orphan receptors, titrating it away from Gal4-TR. Indeed, studies in vitro have shown that 9-cis-RA enhanced homodimerization by RXR on DNA (56), while with coexpressed RXR␣ and TR␣ in CV-1 cells, the addition of 9-cis-RA or RXRspecific ligands augmented formation of RXR homodimers, thereby inhibiting T 3 -dependent activation via TR (57) .
We have shown that the solution interaction between the ligand-binding domains of TR and RXR is markedly enhanced by T 3 . Although TR can clearly form unliganded complexes with RXR on cognate response elements to mediate silencing of basal transcription in many contexts (40) , the ability to form TR⅐RXR heterodimers in solution may confer certain advantages. First, since RXR is a factor common to the signaling pathways of a number of other nuclear receptors, it might not always be expedient for RXR to be sequestered into DNA-bound unliganded receptor complexes, except when in a repressing role. Accordingly, ligand-dependent dimerization in solution would facilitate channeling of RXR to the desired signaling pathway and may also confer a negative regulatory influence on other receptor signaling pathways requiring this factor. We therefore propose that ligand-enhanced heterodimerization prior to DNA binding may constitute an additional early level of control in nuclear receptor-mediated gene expression.
